Stock Price
109.14
Daily Change
-6.48 -5.60%
Monthly
-23.57%
Yearly
60.22%
Q2 Forecast
106.95

Insmed reported $-163.56M in Net Income for its fiscal quarter ending in March of 2026.





Net Income Change Date
BioMarin Pharmaceutical USD 105.53M 152.1M Mar/2026
Cytokinetics USD -206.03M 23M Mar/2026
DBV Technologies USD -33.16M 8.71M Sep/2025
Gilead Sciences USD 2.02B 162M Mar/2026
Heron Therapeutics USD -2.95M 14.54M Dec/2025
Insmed USD -163.56M 164.92M Mar/2026
Novartis USD 2.41B 1.52B Dec/2025
Regeneron Pharmaceuticals USD 727.2M 117.4M Mar/2026
Sarepta Therapeutics USD 330.96M 743.18M Mar/2026
Ultragenyx Pharmaceutical USD -185M 56M Mar/2026
Vertex Pharmaceuticals USD 1.03B 159.7M Mar/2026